FLT3 Inhibitors in the Management of Acute Myeloid Leukemia

Author(s): E. Zappone*, M. Defina, L. Aprile, G. Bartalucci, A. Gozzetti, M. Bocchia

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 8 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


In recent years there has been a great improvement in molecular characterization of acute myeloid leukemia (AML) allowing the stratification of patients in different rate of risk. Patients with FLT3 mutated AML have poor prognosis because of resistance to induction chemotherapy or early relapse. Several first and second generation molecules, able to inhibit FLT3 signaling have been developed and many single agent or combination studies are ongoing. Of these, quizartinib seems to have the best clinical activity. Unfortunately, resistance to FLT3 inhibitors has been observed and many scientists are currently investigating new strategy to restore sensitivity to FLT3 inhibitors.

Keywords: Acute myeloid leukemia, FLT3, inhibitors, molecular target, prognosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 27 July, 2017
Page: [1028 - 1032]
Pages: 5
DOI: 10.2174/1871520616666161010162737
Price: $65

Article Metrics

PDF: 66